Global Acquired Hemophilia Drugs Market Size, Share & Trends Analysis Report, By Type (Hemophilia A, Hemophilia B, and Hemophilia C), By Treatment (On-Demand and Prophylaxis), By Therapy (Replacement Therapy, ITI Therapy, and Gene Therapy), By Distribution Channel (Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy) Forecast (2021-2027)
The global acquired hemophilia drugs market is anticipated to grow at a considerable CAGR during the forecast period. The major factors driving the growth of the market include the rising burden of rare disorder among population globally, increasing awareness of hemophilia, and government contribution towards prevention and control of such disease. Moreover, significant investment by key pharmaceutical companies in R&D of novel therapies for hemophilia is also propelling the expansion of market growth.
The global acquired hemophilia drugs market is segmented based on type, treatment, therapy, and distribution channel. Based on type, the market is sub-segmented into hemophilia A, hemophilia B, and hemophilia C. On the basis of treatment, the market is sub-segmented into on-demand and prophylaxis. Based on therapy, the market is sub-categorized into replacement therapy, ITI therapy, and gene therapy. On the basis of distribution channel, the market is sub-segmented into hospital pharmacy, online pharmacy, and retail pharmacy.
Geographically, the global acquired hemophilia drugs market covers the analysis of four major regions including North America (the US and Canada), Europe (UK, Germany, Italy, Spain, France, and Rest of Europe), Asia-Pacific (China, Japan, India, and Rest of Asia-Pacific), and the Rest of the World.
Some of the companies operating in the global acquired hemophilia drugs market include Shire (Baxalta); CSL Behring; Pfizer, Inc.; Bayer AG; BioMarin, Spark Therapeutics, Inc.; Genzyme Corp., and others.
The global acquired hemophilia drugs market is anticipated to grow at a considerable CAGR during the forecast period. The major factors driving the growth of the market include the rising burden of rare disorder among population globally, increasing awareness of hemophilia, and government contribution towards prevention and control of such disease. Moreover, significant investment by key pharmaceutical companies in R&D of novel therapies for hemophilia is also propelling the expansion of market growth.
The global acquired hemophilia drugs market is segmented based on type, treatment, therapy, and distribution channel. Based on type, the market is sub-segmented into hemophilia A, hemophilia B, and hemophilia C. On the basis of treatment, the market is sub-segmented into on-demand and prophylaxis. Based on therapy, the market is sub-categorized into replacement therapy, ITI therapy, and gene therapy. On the basis of distribution channel, the market is sub-segmented into hospital pharmacy, online pharmacy, and retail pharmacy.
Geographically, the global acquired hemophilia drugs market covers the analysis of four major regions including North America (the US and Canada), Europe (UK, Germany, Italy, Spain, France, and Rest of Europe), Asia-Pacific (China, Japan, India, and Rest of Asia-Pacific), and the Rest of the World.
Some of the companies operating in the global acquired hemophilia drugs market include Shire (Baxalta); CSL Behring; Pfizer, Inc.; Bayer AG; BioMarin, Spark Therapeutics, Inc.; Genzyme Corp., and others.
Market Segmentation
- Global Acquired Hemophilia Drugs Market Research and Analysis by Type
- Global Acquired Hemophilia Drugs Market Research and Analysis by Treatment
- Global Acquired Hemophilia Drugs Market Research and Analysis by Therapy
- Global Acquired Hemophilia Drugs Market Research and Analysis by Distribution channel
The Report Covers
- Comprehensive research methodology of the global acquired hemophilia drugs market.
- This report also includes a detailed and extensive market overview with key analyst insights.
- An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
- Analysis of regional regulations and other government policies impacting the global acquired hemophilia drugs market.
- Insights about market determinants that are stimulating the global acquired hemophilia Drugs market.
- Detailed and extensive market segments with the regional distribution of forecasted revenues.
- Extensive profiles and recent developments of market players.
Table of Contents
1. Report Summary
2. Market Overview and Insights
3. Market Determinants
4. Market Segmentation
5. Regional Analysis
6. Company Profiles
List of Tables
List of Figures
Companies Mentioned
A selection of companies mentioned in this report includes:
- Aptevo Therapeutics
- Bayer AG
- CSL Behring
- Genzyme Corp.
- Grifols SA
- F. Hoffman La Roche Ltd.
- Octapharma AG
- Pfizer Inc
- Spark Therapeutics, Inc.
- Takeda Pharmaceutical Co. Ltd.
